Влияние рисперидона на нейрокогнитивный дефицит при шизофрении
Рекомендуемое оформление библиографической ссылки:
Вазагаева Т.И. Влияние рисперидона на нейрокогнитивный дефицит при шизофрении // Российский психиатрический журнал. 2015. №2. С. 76-81.
В обзорной статье рассматриваются возможные механизмы когнитотропных эффектов рисперидона у пациентов с шизофренией. Описываются результаты клинических исследований, посвященных изучению влияния рисперидона на нейрокогнитивный дефицит, ассоциированного с динамикой негативной и позитивной симптоматики шизофрении, сравнительных когнитотропных эффектов рисперидона и других антипсихотических препаратов первого и второго поколения. Приводятся предварительные данные, подтверждающие благоприятное воздействие на нейрокогнитивные показатели пациентов, приверженность низким дозам рисперидона на этапе поддерживающей фармакотерапии шизофрении.
1. Завьялова Н.Е. Динамика психопатологических расстройств у пациентов с острой шизофренией при применении рисперидона и галоперидола // Соврем. терапия психических расстройств. - 2013. - № 4. - C. 19-24. 2. Мосолов С.Н., Кабанов С.О. Нейрокогнитивный дефицит у больных параноидной шизофренией в процессе терапии кветиапином, рисперидоном и галоперидолом // Психиатрия. - 2005. - № 1. - С. 38-49. 3. Desamericq G., Schurhoff F., Meary A. et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis // Eur. J. Clin. Pharmacol. - 2014. - Vol. 70, N 2. - P. 127-134. 4. Dickinson D., Ramsey M.E., Gold J.M. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia // Arch. Gen. Psychiatry. - 2007. - Vol. 64, N 5. - P. 532-542. 5. Elie D., Poirier M., Chianetta J. et al. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder // J. Psychopharmacol. - 2010. - Vol. 24. - P. 1037-1044. 6. Gallhofer B., Bauer U., Lis S. et al. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs // Eur. Neuropsychopharmacol. - 1996. - Vol. 6, N 2. - P. 13-20. 7. Glahn D.C., Almasy L., Blangero J. et al. Adjudicating neurocognitive endophenotypes for schizophrenia // Am. J. Med. Genet. B. Neuropsychiatr. Genet. - 2007. - Vol. 144B, N 2. - P. 242-249. 8. Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment // Am. J. Psychiatry. - 2001. - Vol. 158. - P. 176-184. 9. Harvey P.D., Rabinowitz J., Eerdekens M., Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial // Am. J. Psychiatry. - 2005. - Vol. 162, N 10. - P. 1888-1895. 10. Hecht E.M., Landy D.C. Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis // Schizophr. Res. - 2012. - Vol. 134. - P. 202-206. 11. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence // Neuropsychology. - 1998. - Vol. 12, N 3. - P. 426-445. 12. Hill S.K., Schuepbach D., Herbener E.S. et al. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia // Schizophr. Res. - 2004. - Vol. 68, N 1. - P. 49-63. 13. Hori H., Noguchi H., Hashimoto R. Antipsychotic medication and cognitive function in schizophrenia // Schizophr. Res. - 2006. - Vol. 86. - P. 138-146. 14. Hughes C., Kumari V., Soni W. et al. Longitudinal study of symptoms and cognitive function in chronic schizophrenia // Schizophr. Res. - 2003. - Vol. 59, N 2-3. - P. 137-146. 15. Keefe R.S., Silva S.G., Perkins D.O., Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis // Schizophr. Bull. - 1999. - Vol. 25. - P. 201-222. 16. Keefe R.S., Bilder R.M., Davis S.M. et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial // Arch. Gen. Psychiatry. - 2007. - Vol. 64, N 6. - P. 633-647. 17. Kim S.W., Chung Y.C., Lee Y.H. et al. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial // Int. Clin. Psychopharmacol. - 2012. - Vol. 27, N 5. - P. 267-274. 18. Kucharska-Pietura K., Tylec A., Czernikiewicz A., Mortimer A. Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs // Med. Sci. Monit. - 2012. - Vol. 18, N 1. - P. 44-49. 19. Manschreck T.C., Boshes R.A. The CATIE schizophrenia trial: results, impact, controversy // Harv. Rev. Psychiatry. - 2007. - Vol. 15, N 5. - P. 245-258. 20. McGurk S.R., Green M.F., Wirshing W.C. et al. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia // Schizophr. Res. - 2004. - Vol. 68. - P. 225-233. 21. Meehl P.E. Schizotaxia revisited // Arch. Gen. Psychiatry. - 1989. - Vol. 46. - P. 935-944. 22. Remberk B., Namyslowska I., Rybakowski F. Cognition and communication dysfunctions in early-onset schizophrenia: effect of risperidone // Prog. Neuropsychopharmacol. Biol. Psychiatry. - 2012. - Vol. 39, N 2. - P. 348-354. 23. Rossi A., Mancini F., Stratta P. et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study // Acta Psychiatr. Scand. - 1997. - Vol. 95, N 1. - P. 40-43. 24. Rybakowski J.K., Drozdz W., Borkowska. Long-term administration of the low-dose risperidone in schizotaxia subjects // Hum. Psychopharmacol. - 2007. - Vol. 22, N 6. - P. 407-412. 25. Sakurai H., Bies R.R., Stroup S.T. et al. Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data // Schizophr. Bull. - 2013. - Vol. 39, N 3. - P. 564-574. 26. Shaufer J., Giangrande E., Weinberger D.R., Dickinson D. The global cognitive impairment in schizophrenia: Consistent over decades and around the world // Schizophr. Res. - 2013. - Vol. 150, N 1. - P. 42-50. 27. Selva-Vera G., Balanza-Martinez V., Salazar-Fraile J. et al. The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia // BMC Psychiatry. - 2010. - Vol. 15, N 10. - P. 47. 28. Stip E., Lussier I. The effect of risperidone on cognition in patients with schizophrenia // Can. J. Psychiatry. - 1996. - Vol. 41, N 8. - P. 35-40. 29. Suzuki H., Gen K. The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia // Hum. Psychopharmacol. - 2012. - Vol. 27, N 5. - P. 470-475. 30. Suzuki H., Gen K., Inoue Y., Hibino H. et al. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial // Int. J. Psychiatry Clin. Pract. - 2014. - Vol. 18, N 1. - P. 58-62. 31. Takeuchi H., Suzuki T., Remington G. et al. Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients With Schizophrenia: An Open-Label, Randomized, Controlled, Pilot Study // Schizophr. Bull. - 2013. - Vol. 39, N 5. - P. 993-998. 32. Thornton A.E., Van Snellenberg J.X., Sepehry A.A., Honer W. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review // J. Psychopharmacol. (Oxford, England). - 2006. - Vol. 20, N 3. - P. 335-346. 33. Tuulio-Henriksson A., Arajarvi R., Partonen T. et al. Familial loading associates with impairment in visual span among healthy siblings of schizophrenia patients // Biol. Psychiatry. - 2003. - Vol. 54, N 6. - P. 623-628. 34. Uchida H., Rajji T.K., Mulsant B.H. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia // J. Clin. Psychopharmacol. - 2009. - Vol. 29. - P. 571-575. 35. Velligan D.I., Mahujin R.K., Diamond P.L. The functional significance of symptomatology and cognitive function in schizophrenia // Schizophr. Res. - 1997. - Vol. 25. - P. 21-31. 36. Ventura J., Thames A.D., Wood R.C. et al. Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits // Schizophr. Res. - 2010. - Vol. 121, N 1-3. - P. 1-14. 37. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia // Int. J. Neuropsychopharmacol. - 2005. - Vol. 8. - P. 457-472.
DOI: http://dx.doi.org/10.24411/1560-957X-2015-1%25x
Метрики статей
Metrics powered by PLOS ALM